Pune, Maharashtra -- (SBWire) -- 02/19/2019 --According to Fact.MR's research report on the global peptide based metabolic disorders therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value more than US$ 8 Bn.
There are several ongoing research activities and technological developments in accordance with medical research activities which focus on treatment of various ailments. Peptide therapeutics are used to treat several of these ailments, of which metabolic disorders are one type. Peptides possess good stability, efficacy, safety, and moreover, they are small in size, and hence can be easily synchronized. These advantages fuel the growth of the global peptide based metabolic disorders therapeutics market. To support the growth, factors such as technological advancements and increased funding in healthcare, and the impressive business growth of biotech and pharmaceutical companies, have spurred the adoption of the peptides used to treat metabolic disorders. Such disorders have risen, and this has called for a rapid development of therapies based on peptides to treat such disorders. North America is anticipated to show higher attractiveness in the global peptide based metabolic disorders therapeutics market.
Request Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=187
North America Domination in the Peptide Based Metabolic Disorders Therapeutics
With respect to the global peptide based metabolic disorders therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share. In terms of revenues, North America is poised to grow at a higher growth rate, registering a CAGR of 10.6% throughout the period of forecast of 2017 to 2022. This region is expected to show the highest market attractiveness index, and is the most lucrative region for the growth of the global peptide based metabolic disorders therapeutics market. Middle East and Africa (MEA) and Latin America regions will show slower growth rate as compared to North America, as well as a comparatively low market revenue share
APEJ Shows a Similar Growth Rate
The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America. APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.
Request/View Toc@ https://www.factmr.com/connectus/sample?flag=T&rep_id=187
Competition Tracking
The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG.
Liraglutide Dominates the Drug Class Category
The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class. The market share of this segment is more than two and a half times than that of the exenatide segment as of 2017. However, it is anticipated that this segment will lose BPS by the end of 2022. The growth of liraglutide segment is slow as compared to the growth rates of the exenatide and others segments throughout the period of forecast.
Exenatide and Others Segments Have a Tie
The exenatide and others segments by drug class show similar growth rate and hence can be said to congruently move along during the period of forecast. However, the exenatide segment enjoys a higher market share than the others segment, more than three times than that of the others segment during 2017 and this trend is expected to run its course throughout the period of forecast. Both these segments are expected to show a gain in the BPS by the end of 2022.
Speak To Research Analyst for Detailed Insights @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=187
Detailed TOC of Global Peptide Based Metabolic Disorders Therapeutics Market by Manufacturers, Regions, Type and Application, Forecast to 2022
1. Global Peptide Based Metabolic Disorders Therapeutics Market - Executive Summary
2. Global Peptide Based Metabolic Disorders Therapeutics Market Overview
2.1. Introduction
2.1.1. Global Peptide Based Metabolic Disorders Therapeutics Market Taxonomy
2.1.2. Global Peptide Based Metabolic Disorders Therapeutics Market Definition
2.2. Global Peptide Based Metabolic Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
2.2.1. Global Peptide Based Metabolic Disorders Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Metabolic Disorders Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region
Access This Report @ https://www.factmr.com/checkout/187/S
3. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Drug
3.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast By Drug, 2012-2022
3.1.1. Liraglutide Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
3.1.1.1. Revenue (US$ Mn) Comparison, By Region
3.1.1.2. Market Share Comparison, By Region
3.1.1.3. Y-o-Y growth Comparison, By Region
3.1.2. Exenatide Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
3.1.2.1. Revenue (US$ Mn) Comparison, By Region
3.1.2.2. Market Share Comparison, By Region
3.1.2.3. Y-o-Y growth Comparison, By Region
3.1.3. Others Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
3.1.3.1. Revenue (US$ Mn) Comparison, By Region
3.1.3.2. Market Share Comparison, By Region
3.1.3.3. Y-o-Y growth Comparison, By Region
4. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Distribution Channel
4.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
4.1.1. Hospital Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Retail Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Online Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
4.1.3.1. Revenue (US$ Mn) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
5. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Region
5.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.1. North America Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.1.1. Revenue (US$ Mn) Comparison, By Drug
5.1.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.2. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.2.1. Revenue (US$ Mn) Comparison, By Drug
5.1.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.3. Europe Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.3.1. Revenue (US$ Mn) Comparison, By Drug
5.1.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.4. Japan Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.4.1. Revenue (US$ Mn) Comparison, By Drug
5.1.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.5. APEJ Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.5.1. Revenue (US$ Mn) Comparison, By Drug
5.1.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.6. MEA Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.6.1. Revenue (US$ Mn) Comparison, By Drug
5.1.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel
And Continue....
List of Figures, Tables and Charts Available in Global Peptide Based Metabolic Disorders Therapeutics Market 2017 by Manufacturers, Regions, Type and Application, Forecast to 2022
TABLE 1 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), 2012-2016
TABLE 2 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), 2017-2022
TABLE 3 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn) and Y-o-Y, 2015-2022
TABLE 4 Global Liraglutide Segment Value (US$ Mn), By Region 2012-2016
TABLE 5 Global Liraglutide Segment Value (US$ Mn), By Region 2017-2022
TABLE 6 Global Liraglutide Segment Market Share, By Region 2012-2016
TABLE 7 Global Liraglutide Segment Market Share, By Region 2017-2022
TABLE 8 Global Liraglutide Segment Y-o-Y, By Region 2015-2022
TABLE 9 Global Exenatide Segment Value (US$ Mn), By Region 2012-2016
TABLE 10 Global Exenatide Segment Value (US$ Mn), By Region 2017-2022
TABLE 11 Global Exenatide Segment Market Share, By Region 2012-2016
TABLE 12 Global Exenatide Segment Market Share, By Region 2017-2022
TABLE 13 Global Exenatide Segment Y-o-Y, By Region 2015-2022
TABLE 14 Global Others Segment Value (US$ Mn), By Region 2012-2016
TABLE 15 Global Others Segment Value (US$ Mn), By Region 2017-2022
And Continue....
FIG. 1 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), 2012-2016
FIG. 2 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn) Forecast, 2017-2022
FIG. 3 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn) and Y-o-Y, 2015-2022
FIG. 4 Global Liraglutide Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 5 Global Liraglutide Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 6 Global Liraglutide Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 7 Global Exenatide Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 8 Global Exenatide Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 9 Global Exenatide Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 10 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 11 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 12 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 13 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 14 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 15 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2015-2022
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - https://theswisstimes.com
Peptide Based Metabolic Disorders Therapeutics Market to Witness Growth Acceleration During 2018-2028
Fact.MR has announced the addition of the “ Peptide Based Metabolic Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2018 to 2028"report to their offering.